Washington Senator’s Campaign Contributions and Legislative Actions Under Scrutiny
State Senator John Braun from Washington has been the recipient of substantial donations from both the pharmaceutical and health insurance sectors throughout his political journey. His voting record shows opposition to various measures aimed at reducing healthcare costs.
Braun is currently vying for the U.S. House seat in Washington’s 3rd District, a position held by Democrat Representative Marie Gluesenkamp Perez.
Financial records reveal that since 2012, Braun has accrued $73,550 from pharmaceutical companies and $37,400 from the health insurance industry. These contributions represent approximately 10% of his total campaign donations.
In a notable 2022 decision, Braun stood with the pharmaceutical industry in opposing a bipartisan legislative proposal to establish a Prescription Drug Affordability Board in Washington. This board’s purpose is to assess medication costs and potentially cap what individuals, state agencies, and insurers are charged.
The AARP highlighted that such a board “could lead to lower insurance premiums, reduce taxpayer spending on health care, and would help ensure people can afford the medication they need.” However, the initiative faced criticism from PhRMA, a trade group for the pharmaceutical sector, which had contributed to Braun’s campaign in 2015 and 2016.
In 2021, Braun similarly opposed a legislative effort permitting Washington to procure, produce, and distribute generic drugs, which are typically more affordable than branded alternatives.
Additionally, in 2020, he voted against a bill facilitating the bulk purchase of insulin by the state to offer it at reduced prices, and another that mandated health insurers in Washington to cover pre-existing conditions.
Despite his legislative track record, Braun maintains that his focus is on affordability and cost reduction. In June, he criticized Gluesenkamp Perez for her stance against “the largest tax cut in history,” even though the tax cut is largely perceived to benefit the wealthy and involves a $1 trillion reduction in Medicaid funding.
Healthcare expenses are anticipated to be a critical topic in the 2026 election cycle, with a June 2026 Gallup poll indicating that Americans’ ability to afford healthcare is at its lowest in five years.
President Donald Trump has endorsed Braun’s campaign.
The post Braun took drug industry money, opposed lower health care costs appeared first on American Journal News.
—
Read More Kitchen Table News
